WASHINGTON — President Trump is trying to do what President Obama failed to accomplish: stand up to the pharmaceutical industry and doctors to change the way that the government pays for drugs.

In a sweeping proposal Thursday that lacked critical details, his Department of Health and Human Services detailed a plan to change the way that Medicare pays for doctor-administered drugs in the Part B program, with one goal of removing the current incentive for doctors to prescribe high-cost drugs. The end goal: to bring down costs for the government and ultimately, for patients.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy